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Dear Editor,
In their publication of the National Institute for Health and
Clinical Excellence single technology appraisal of retiga-
bine, Craig et al. [1] report the results of the network com-
parison of retigabine and other anti-epileptic treatments.
We find this to be an interesting article as well as the
entire series of single technology appraisal articles pub-
lished in PharmacoEconomics, considering that single
appraisals are common in the Health Technology Assess-
ment process for drug reimbursement in Poland.
We agree with Craig et al.’s conclusions [1], although
we believe that the relationship between the dose of reti-
gabine and the effect should be more intensively examined,
especially in comparison with other treatments.
The available clinical data (cf. Craig et al. for details [1,
2]) allows for investigation of dose-response effects. The
conclusions from a dose-dependent model may be more
useful for clinicians who are only at the beginning of their
experience with a new anti-epileptic drug, such as retiga-
bine. Presentation of retigabine dose corresponding to the
effectiveness or safety profile of other interventions would
allow for better planning of the treatment, such as in
determining the magnitude of the retigabine dose increase
in the titration phase.
Using the clinical data for the intent-to-treat population
(titration and maintenance phase combined), Craig et al. [1]
reported low heterogeneity of the effect after pooling all
doses of retigabine. The lack of dose dependence is, however,
counter-intuitive and, acknowledging the homogeneity of the
trials of retigabine, meta-regression should be carried out,
even with the assumption that the only predictor of the effect
is the actual dose of retigabine (due to the insufficient number
of trials for conducting a more complex model [3]).
For retigabine, lacosamide and eslicarbazepine—treat-
ments with available clinical data allowing plausible
analysis of the dose-effect relationship—we conducted a
meta-analysis and meta-regression. The results of our cal-
culations are shown in Table 1.
The meta-regression results are consistent with the
results of a meta-analysis of individual doses, are associ-
ated with lower rates of heterogeneity (Cochrane Q test;
data not shown), and are intuitive (increasing the dose we
expect a higher effect, particularly in a trial with a forced
titration phase).
As an example, we found that for each daily dose of a
200-mg increase of retigabine, eslicarbazepine and laco-
samide, the odds for the response (with at least a 50 %
reduction in the frequency of seizures) increases were:
odds ratio (OR) 1.24 (95 % credible interval [CrI]:
1.16–1.33), OR 1.22 (95 % CrI: 1.13–1.33) and OR 1.41
(95 % CrI: 1.22–1.64), respectively, with a significant
dose-dependent effect across all treatments (p \ 0.001).
Likewise we found a highly significant dose-dependent
effect across all treatments for the rate of adverse events
leading to discontinuation (p \ 0.0001), yet a nonsignifi-
cant (retigabine, lacosamide) or small (eslicarbazepine;
p = 0.0276) impact of dose variation on the rate of seizure
freedom (most likely due to limitations of rare event
analysis).
Expanding the meta-regression model with an indirect
comparison, it could be estimated that in order to obtain the
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same responder rate as for retigabine at a dose of 600 mg/
d, eslicarbazepine should be given at a dose of 632 mg/d
(95 % CrI: 395–1091) and lacosamide at a dose of 411 mg/
d (95 % CrI: 247–909). Since the equivalent dosage could
be quite different with different outcome measures
(Table 2), the most suitable outcome selection should be
consulted with practitioners or the competition/weighing of
the different events should be included.
Furthermore, the proposed approach could be helpful in
identifying the potential differences in the safety and
effectiveness of a new anti-epileptic drug. In our example,
the point estimate of equivalent doses might indicate that
retigabine could be associated with a lower risk of dis-
continuation due to adverse events and with a similar
response rate when compared with lacosamide or
eslicarbazepine (with an equal safety profile achieved at a
lower dose than the equal rate of response). However, this
conclusion would need further examination.
In conclusion, a simplified solution was shown to be
only one of the possible approaches to the investigation of
dose-response effects. We are aware of the limitations of
the proposed model and indicate that a more accurate
approach would be required; i.e. the inclusion of all treat-
ments and all events (in particular the response to the
treatment and withdrawal due to adverse events or serious
adverse events), which additionally requires dealing with
methodological issues associated with the relationship of
the safety profile to the effectiveness of anti-epileptic
treatments. We believe, however, that even with certain
limitations a similar approach would be more informative
Table 1 Effectiveness of retigabine, lacosamide and eslicarbazepine in comparison with placebo: odds ratio with 95 % CI (meta-analysis
results) or 95 % CrI (meta-regression results) in brackets (ITT population)
Responder rate Rate of seizure freedom Rate of adverse events leading to discontinuation
Meta-analysisa Meta-regressionb Meta-analysisa Meta-regressionb Meta-analysisa Meta-regressionb
Retigabine
Pooled 2.79 (2.08–3.76) NA 2.54 (0.92–6.98) NA 2.94 (2.03–4.27) NA
600 mg/d 1.99 (1.33–3.01) 1.91 (1.56–2.36) 0.98 (0.26–3.66) 2.18 (0.70–7.69) 1.97 (1.18–3.28) 2.01 (1.54–2.60)
900 mg/d 2.88 (1.93–4.31) 2.64 (1.95–3.62) 2.85 (0.90–9.06) 3.22 (0.58–21.33) 2.98 (1.82–4.86) 2.84 (1.91–4.19)
1200 mg/d 3.28 (2.16–4.96) 3.65 (2.43–5.56) 4.08 (1.01–16.46) 4.76 (0.49–59.15) 3.42 (2.09–5.61) 4.02 (2.37–6.75)
Lacosamide
Pooled 2.13 (1.61–2.82) NA 2.55 (0.87–7.50) NA 3.75 (2.26–6.21) NA
200 mg/d 1.63 (1.11–2.39) 1.41 (1.22–1.64) 1.85 (0.50–6.88) 2.08 (0.99–6.78) 1.67 (0.82–3.40) 1.93 (1.59–2.41)
400 mg/d 2.33 (1.71–3.19) 1.98 (1.49–2.70) 2.76 (0.87–8.74) 4.31 (0.97–46.03) 3.95 (2.31–6.76) 3.74 (2.51–5.81)
600 mg/dc 2.61 (1.67–4.08) 2.79 (1.82–4.43) 7.31 (0.91–58.99) 8.95 (0.96–312.25) 7.61 (3.76–15.41) 7.24 (3.98–14.00)
Eslicarbazepine
Pooled 2.52 (1.77–3.58) NA 3.33 (1.17–9.48) NA 3.36 (1.85–6.10) NA
400 mg/d 1.66 (0.98–2.81) 1.50 (1.27–1.77) 1.03 (0.21–5.20) 1.68 (1.13–2.72) 2.47 (1.00–6.12) 1.74 (1.35–2.21)
800 mg/d 2.78 (1.87–4.13) 2.24 (1.62–3.14) 4.22 (1.40–12.80) 2.83 (1.27–7.39) 2.85 (1.48–5.51) 3.02 (1.83–4.91)
1200 mg/d 3.06 (2.16–4.96) 3.36 (2.05–5.56) 4.13 (1.35–4.96) 4.76 (1.43–20.09) 5.09 (2.72–9.51) 5.24 (2.47–10.87)
OR odds ratio, CI confidence interval, CrI credible interval, NA not applicable, ITT intent-to-treat
a Mantel-Haenszel fixed-effects model included studies identified by Craig et al. [1, 2]
b Bayes random effect logistic model [3] with the dose of each drug as the only independent variable
c Dosage not recommended [4]
Table 2 Dose of lacosamide and eslicarbazepine corresponding to the effectiveness or safety profile of retigabine at a dose of 600 mg/d
Outcome Dose of lacosamide Dose of eslicarbazepine
Responder rate 411 mg/d (95 % CrI: 247–909a) 632 mg/d (95 % CrI: 395–1091)
Rate of seizure freedom 511 mg/d (–b) 220 mg/d (–b)
Rate of adverse events leading to discontinuation 216 mg/d (95 % CrI: 75–568) 490 mg/d (95 % CrI: 174–1383a)
CrI credible interval
a Higher than the maximum recommended dose [4, 5]
b Uncertainty range greatly exceeding the dosage in clinical practice and/or being counter-intuitive (negative value)
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to the public and practitioners than the approach adopted
by Craig et al. [1].
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